12-week high-intensity interval training for recent survivors of childhood and young-adult Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot tests the feasibility of a remotely supervised 12-week HIIT program in survivors who completed Hodgkin lymphoma treatment within the past 24 months. Participants receive an iPad and heart rate monitor and join live web-based HIIT sessions led by exercise physiologists. Researchers conduct baseline and post-intervention assessments including exercise testing, body composition, autonomic function, peripheral neuropathy screening, and blood biomarkers of biological aging. The study will report participation and completion rates and collect preliminary data on cardiorespiratory fitness, physical function, and physical activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
* Participant is between the ages of \>10 and \<25 years old the time of enrollment.
* Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
* Participant has been medically cleared to participate in physical activity.
* Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion Criteria:

* Participant has evidence of relapsed disease.
* Participant has a diagnosis of acute heart failure.
* Participant reports currently participating in HIIT training or \>420 minutes per week of moderate to vigorous physical activity.
* Female participant who is currently pregnant.

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Amy Berkman, MD — St. Jude Children's Research Hospital
• Study coordinator: Amy Berkman, MD
• Email: referralinfo@stjude.org
• Phone: 888-226-4343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• JLM019 Injection in Adults with Advanced Cancers

  This study tests JLM019 Injection in adults with advanced solid tumors or relapsed/refractory lymphomas to see if it’s safe and tolerable.

  Recruiting Phase 1 Jecho Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07623850

• Cord blood transplant for children and young adults with blood cancers.

  This study will test whether a cord blood transplant given as a first or second transplant can help children and young adults with leukemia, myelodysplasia, or lymphoma who lack a matched donor.

  Recruiting Phase 2 Memorial Sloan Kettering Cancer Center · New York, New York · NCT07566377

• Nivolumab plus AVD for newly diagnosed early-stage non-bulky classical Hodgkin lymphoma in young patients

  This study tests whether nivolumab added to AVD can help children, teens, and young adults with newly diagnosed early-stage non-bulky Hodgkin lymphoma.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07551583

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Autologous CD45 base-edited stem cells plus CART-45 cells for relapsed or refractory hematologic cancers

  This phase 1 study tests whether a patient’s own edited stem cells and CART-45 cells can be given safely to treat relapsed or refractory B-cell and T-cell lymphomas and Hodgkin lymphoma.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07451054

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.